Dry Eye News and Research

RSS
Dry eye is one of the most common complaints seen by eye doctors, accounting for nearly one fourth of all office visits. Caused by insufficient tear production or excessive tear evaporation, dry eye can be a mild, episodic feeling of discomfort associated with certain circumstances, such as exposure to dry, hot or windy environments; however, it can also be a chronic medical condition that, if left untreated, may lead to increased risk of infection or visual impairment.
VEGF-B can regenerate damaged peripheral nerves without causing growth of new blood vessels

VEGF-B can regenerate damaged peripheral nerves without causing growth of new blood vessels

Rigel Pharmaceuticals reports net loss of $20.9 million for third quarter of 2014

Rigel Pharmaceuticals reports net loss of $20.9 million for third quarter of 2014

RegeneRx to begin RGN-259 Phase 3 trials for treatment of neurotrophic keratopathy

RegeneRx to begin RGN-259 Phase 3 trials for treatment of neurotrophic keratopathy

Researchers develop nanoparticle eye drops to combat dry eye syndrome

Researchers develop nanoparticle eye drops to combat dry eye syndrome

RPS Diagnostics receives CE mark for FebriDx test

RPS Diagnostics receives CE mark for FebriDx test

Center Director of Omni Eye Surgery describes promising option for managing lid disease

Center Director of Omni Eye Surgery describes promising option for managing lid disease

Around 9.6% of women diagnosed with dry eye disease, treated with artificial tear eye drops

Around 9.6% of women diagnosed with dry eye disease, treated with artificial tear eye drops

Phase 2 study: Rigel's R348 fails to meet endpoints in patients with dry eye disease

Phase 2 study: Rigel's R348 fails to meet endpoints in patients with dry eye disease

Shire, ArmaGen partner to develop AGT-182 drug for treatment of Hunter syndrome

Shire, ArmaGen partner to develop AGT-182 drug for treatment of Hunter syndrome

Parents severely underestimate time children spend on digital devices

Parents severely underestimate time children spend on digital devices

Rigel initiates Phase 3 clinical program for fostamatinib in patients with ITP

Rigel initiates Phase 3 clinical program for fostamatinib in patients with ITP

Chinese FDA accepts Lee's IND for Phase 2 dry eye study

Chinese FDA accepts Lee's IND for Phase 2 dry eye study

ARIAD reports data from Iclusig Phase 2 trial in adult patients with gastrointestinal stromal tumors

ARIAD reports data from Iclusig Phase 2 trial in adult patients with gastrointestinal stromal tumors

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

Rand Eye Institute's hurricane eye safety tips

Rand Eye Institute's hurricane eye safety tips

Computer simulations offer potential treatment option for dry eye syndrome

Computer simulations offer potential treatment option for dry eye syndrome

Shire intends to submit NDA for lifitegrast to treat dry eye disease

Shire intends to submit NDA for lifitegrast to treat dry eye disease

Eleven Biotherapeutics reports financial results and operational highlights for Q1 2014

Eleven Biotherapeutics reports financial results and operational highlights for Q1 2014

Rigel Pharmaceuticals reports net loss of $22.3 million for first quarter 2014

Rigel Pharmaceuticals reports net loss of $22.3 million for first quarter 2014

New research aids development of better treatments for dry eye

New research aids development of better treatments for dry eye